Significance of donor-derived isoagglutinins in ABO-incompatible hematopoietic stem cell transplantation

Journal of Clinical Laboratory Analysis

Volumn 22, Issue 6, 2008, Pages 383-390

  Chung, Hee Jung ^a   Lee, Je Hwan ^a   Kwon, Seog Woon ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

ABO incompatibility; Donor derived isoagglutinin (DDI); Graft versus host disease (GVHD); Hematopoietic stem cell transplantation (HSCT)

Indexed keywords

AGGLUTININ; BUSULFAN; CYCLOPHOSPHAMIDE; DONOR DERIVED ISOAGGLUTININ DERIVATIVE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; BLOOD DONOR; BLOOD GROUP ABO INCOMPATIBILITY; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME;

ABO BLOOD-GROUP SYSTEM; ACUTE DISEASE; ADOLESCENT; ADULT; AGGLUTININS; BLOOD GROUP INCOMPATIBILITY; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 56749130817     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20269     Document Type: Article

References (28)

1. Gratwohl A, Passweg J, Baldomero H, Urbano-Ispizua A. Hematopoietic stem cell transplantation activity in Europe 1999. Bone Marrow Transplant 2001;27:899-916.
2. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175-181.
3. Worel N, Greinix HT, Schneider B, et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: A major ABO mismatch means problems. Transfusion 2000;40:543-550.
4. Oziel-Taieb S, Faucher-Barbey C, Chabannon C, et al. Early and fatal immune haemolysis after so-called 'minor' ABO-incompatible peripheral blood stem cell allotransplantation. Bone Marrow Transplant 1997;19:1155-1156.
5. Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 2001;98:1687-1694.
6. Benjamin RJ, Connors JM, McGurk S, Churchill WH, Antin JH. Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 1998;4:151-156.
7. Pihlstedt P, Paulin T, Sundberg B, Nilsson B, Ringden O. Blood transfusion in marrow graft recipients. Ann Hematol 1992;65:66-70.
8. Stussi G, Muntwyler J, Passweg JR, et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;30:87-93.
9. Bacigalupo A, Van Lint MT, Occhini D, et al. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation 1988;45:1091-1094.
10. Lee JH, Lee KH, Kim S, et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;25:179-184.
11. Lee JH, Lee JH, Choi SJ, et al. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol 2003;120:702-710.
12. Perruche S, Kleinclauss F, Tiberghien P, Saas P. B cell allogeneic responses after hematopoietic cell transplantation: Is it time to address this issue? Transplantation 2005;79:S37-S39.
13. Tabilio A, Falzetti F, Zei T, et al. Graft engineering for allogeneic haploidentical stem cell transplantation. Blood Cells Mol Dis 2004;33:274-280.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
15. Lapierre V, Oubouzar N, Auperin A, et al. Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation. Blood 2001;97:2580-2586.
16. Kansu E. The pathophysiology of chronic graft-versus-host disease. Int J Hematol 2004;79:209-215.
17. Ichiki Y, Bowlus CL, Shimoda S, et al. T cell immunity and graft-versus-host disease (GVHD). Autoimmun Rev 2006;5:1-9.
18. Arai S, Vogelsang GB. Management of graft-versus-host disease. Blood Rev 2000;14:190-204.
19. Schultz KR, Paquet J, Bader S, HayGlass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995;16:289-295.
20. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-233.
21. Shimoni A, Hardan I, Avigdor A, et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003;122:457-464.
22. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003;9:505-511.
23. Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 2004;20:517-527.
24. Badros A, Tricot G, Toor A, et al. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion 2002;42:205-209.
25. Keever-Taylor CA, Bredeson C, Loberiza FR, et al. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant 2001;7:620-630.
26. Mehta J, Powles R, Treleaven J, et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplant 1996;18:741-746.
27. Erker CG, Steins MB, Fischer RJ, et al. The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation. Transfusion 2005;45:1382-1390.
28. Rozman P, Kosir A, Bohinjec M. Is the ABO incompatibility a risk factor in bone marrow transplantation? Transpl Immunol 2005;14:159-169.